CTR20262629 TQA Gel Patch Osteoarthritis, Knee Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a specific protocol into a decision-ready landscape.Asset, and Company & Deal Intelligence MCP evidence.Explore PatSnap MCP Servers to reproduce the workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Recheck the live record before operational decisions.
Why this trial is differentiated
CTR20262629 tests TQA Gel Patch in Osteoarthritis, Knee. Unlike asset-only screens, this protocol highlights how intervention delivery, endpoint choice, enrollment and execution setting can create clinical white space. The study is indexed as Phase 2 with Not yet recruiting status.
Trial landscape table
| Field | Indexed detail |
|---|---|
| Registration | CTR20262629 |
| Official title | TQA Gel Patch ( ) II |
| Phase / status | Phase 2 / Not yet recruiting |
| Intervention | TQA Gel Patch |
| Sponsor | Sailing Pharmaceutical Technology Group Co., Ltd. |
| Geography | China |
| Enrollment | 240 |
| Primary endpoint | Not reported |
| Endpoint time frame | Not reported in English |
| Primary completion / readout proxy | Not reported |
Design and endpoint interpretation
Allocation is Randomized, masking is Double-blind, and the intervention model is Parallel Assignment. The primary endpoint—not reported—defines the uncertainty this study can resolve. Enrollment of 240 and geography in China influence precision, feasibility and external validity.
Benchmark and readout context
PatSnap Clinical Trial Result records provide structured endpoint benchmarks for adjacent programs. For procedure-led, behavioral or device-like interventions, direct cross-trial comparisons may be especially fragile because technique, operator experience, baseline severity and assessment schedules differ. The appropriate benchmark is therefore the endpoint architecture and clinically meaningful effect threshold, not a single headline number.
Build a living monitor:connect to PatSnap MCP Servers to track protocol amendments, completion dates and newly indexed results.
Asset and sponsor context
Drug & Asset context: TQA Gel Patch is the protocol intervention. No separate normalized investigational-drug entity is required where the program is procedure-, device-, behavioral- or care-pathway-led; this distinction prevents false asset attribution.
Company & Deal Intelligence context: Sailing Pharmaceutical Technology Group Co., Ltd. — http://www.sailing.com.cn.
Sponsor capability still matters: multicenter reach, intervention standardization, operator training, data quality and confirmatory funding determine whether a signal becomes transferable evidence.
White space
- Standardization: reproducible intervention delivery across sites and operators.
- Patient selection: prospective criteria identifying the population most likely to benefit.
- Clinical meaning: endpoints tied to symptoms, function, recurrence, treatment burden or quality of life.
- Durability: follow-up long enough to distinguish transient change from lasting benefit.
- External validity: evidence across additional geographies and real-world settings.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, readout timing, first result indexing and sponsor partnerships. For a focused trial, a change in technique or endpoint can be as consequential as the final data release.
Bottom line
CTR20262629 provides a specific view of Osteoarthritis, Knee development through TQA Gel Patch. Its strategic value will depend on whether the design produces clinically meaningful, reproducible and operationally credible evidence.
Ready to reproduce this analysis?Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence in an SEO-ready workflow.
